Dimerix (ASX:DXB) Shareholder Yield % : -5.63% (As of Dec. 2025)


ASX:DXB Dimerix Ltd ASX:DXB
32 GF Score
Price A$0.19
! 3 Warning Signs
View Full Analysis

What is Dimerix Shareholder Yield %?

Dimerix ASX:DXB -5.00% 32 Shareholder Yield % is -5.63% as of Dec. 2025. GuruFocus rates ASX:DXB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,300 Biotechnology companies, Dimerix ranks worse than 62% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Dimerix's Shareholder Yield % was -5.63%.


Dimerix  (ASX:DXB) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Dimerix Shareholder Yield % Related Terms


Dimerix Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Dimerix's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimerix Shareholder Yield % Chart

Dimerix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.90 -43.98 -46.70 -7.87 -2.00

Dimerix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.62 -7.87 -11.41 -2.00 -1.94

ASX:DXB vs VRTX, REGN, ALNY: Shareholder Yield % Comparison

For the Biotechnology subindustry, Dimerix's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dimerix Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dimerix's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Dimerix's Shareholder Yield % falls into.


ASX:DXB
32GF Score
Dimerix Ltd ASX:DXB
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimerix Shareholder Yield % Calculation

Dimerix's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-1.97 %+0.03 %
=-1.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -5.63% mean?
Dimerix (ASX:DXB) has a Shareholder Yield % of -5.63% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Dimerix and its competitors. According to the industry distribution chart, Dimerix ranks #806 out of 1300 companies in the Biotechnology industry, placing it in the top 62%.
Is Dimerix's Shareholder Yield % too high?
Dimerix's current Shareholder Yield % is -5.63%. Based on the distribution chart, Dimerix ranks #806 out of 1300 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dimerix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dimerix ranks #806 out of 1300 companies for Shareholder Yield %. This places Dimerix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Dimerix and its competitors. Dimerix's current Shareholder Yield % is -5.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current Shareholder Yield % of -5.63%. The current Shareholder Yield % is -5.63%. Dimerix's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current Shareholder Yield % is -5.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dimerix Business Description

Address 425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score

Get the complete analysis for ASX:DXB

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.19
Price